ArticleCurrent medicinal chemistry2026
Decoding PRTFDC1's Role in Lung Adenocarcinoma: From Gene Expression to Clinical Implications.
Article in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transcriptomic Insights Reveal PRTFDC1 as a Novel Regulator of Myogenic Differentiation in Sujiang Pig Satellite Cells.Veterinary sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study aims to elucidate the role of Phosphoribosyl Transferase Domain Containing 1 (PRTFDC1) in Lung Adenocarcinoma (LUAD) through bioinformatics analysis and experimental validation, exploring its potential as a biomarker for prognosis and treatment response.
methodsWe analyzed PRTFDC1 gene expression patterns in 539 LUAD and 59 normal lung tissue samples from The Cancer Genome Atlas (TCGA). Using bioinformatics tools, we examined the correlation between PRTFDC1 expression and clinical characteristics, immune infiltration, Tumor Mutation Burden (TMB), and drug responsiveness. Experimental validation was conducted in LUAD cell lines (A549 and HCC-78) through the overexpression of PRTFDC1, followed by cell proliferation and cell cycle assays.
resultsPRTFDC1 expression was significantly elevated in LUAD compared to normal tissues, correlating with poorer Progression-Free Survival (PFS) and Disease-Specific Survival (DSS). PRTFDC1 was associated with immune cell infiltration, TMB, and mRNA stemness index (mRNAsi). Overexpression of PRTFDC1 in LUAD cell lines promoted cell proliferation and cell cycle progression, mediated by Threonine Tyrosine Kinase (TTK). DISCUSSION: The findings suggest that PRTFDC1 may serve as an independent prognostic marker for LUAD, influencing tumor progression and immune response. The correlation with TTK indicates a potential mechanism for PRTFDC1's impact on cell proliferation. However, further research is needed to validate these findings in larger cohorts and explore the underlying molecular mechanisms.
conclusionPRTFDC1 is a promising biomarker for LUAD prognosis and treatment response, with potential implications for targeted therapies and personalized medicine.
Indexed as
Identifiers
40873179What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.